Position in NVS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$706,649
+$89,235 QoQ
Shares Held
4,509
+11.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#748
of 1,603 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Ausdal Financial Partners, Inc. holds $34,343,984 across 14 Drug Manufacturers - General names. NVS ranks #8 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
8,231 | $9,872,508 | |
| 2 | ABBV |
AbbVie Inc.
|
39,096 | $9,838,116 | |
| 3 | JNJ |
Johnson & Johnson
|
18,662 | $4,739,587 | |
| 4 | MRK |
Merck & Co., Inc.
|
23,933 | $3,075,390 | |
| 5 | GILD |
Gilead Sciences, Inc.
|
15,985 | $2,019,544 | |
| 6 | AMGN |
Amgen Inc
|
2,893 | $1,047,612 | |
| 7 | PFE |
Pfizer Inc
|
41,679 | $1,003,629 | |
| 8 | NVS |
Novartis AG
This page
|
4,509 | $706,649 |
All Filings in NVS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $706,649 | 4,509 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $617,414 | 4,042 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $281,116 | 2,039 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $255,325 | 1,991 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||